BC Week In Review | Nov 30, 2018
Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Nov. 27, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin...
BC Extra | Nov 28, 2018
Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Tuesday, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin receptor...
BC Extra | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
BC Week In Review | Sep 15, 2017
Company News

Gene therapy company Rocket finds public path

Ophthalmic play Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) will merge with gene therapy company Rocket Pharmaceuticals Ltd. (New York, N.Y.). The combined company will retain Rocket's name and will be located in New York. The partners expect...
BC Extra | Sep 12, 2017
Company News

Gene therapy company Rocket finds public path

Ophthalmic play Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) will merge with gene therapy company Rocket Pharmaceuticals Ltd. (New York, N.Y.). The combined company will retain Rocket's name and will be located in New York. The partners expect...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Jan 6, 2017
Clinical News

Trabodenoson: Ph III MATrX-1 data

Top-line data from the double-blind, U.S. Phase III MATrX-1 trial in 303 patients with primary open-angle glaucoma or ocular hypertension showed that once-daily 3% and 6% and twice-daily 4.5% topical trabodenoson for 3 months all...
BC Extra | Jan 3, 2017
Clinical News

Inotek plummets on Phase III glaucoma miss

Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) sank $4.35 (71%) to $1.75 after it said trabodenoson ( INO-8875 ) monotherapy missed the primary endpoint of the Phase III MATrX-1 trial to treat primary open-angle glaucoma or ocular hypertension. Inotek said...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
Items per page:
1 - 10 of 86
BC Week In Review | Nov 30, 2018
Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Nov. 27, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin...
BC Extra | Nov 28, 2018
Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Tuesday, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin receptor...
BC Extra | Dec 12, 2017
Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
BC Week In Review | Sep 15, 2017
Company News

Gene therapy company Rocket finds public path

Ophthalmic play Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) will merge with gene therapy company Rocket Pharmaceuticals Ltd. (New York, N.Y.). The combined company will retain Rocket's name and will be located in New York. The partners expect...
BC Extra | Sep 12, 2017
Company News

Gene therapy company Rocket finds public path

Ophthalmic play Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) will merge with gene therapy company Rocket Pharmaceuticals Ltd. (New York, N.Y.). The combined company will retain Rocket's name and will be located in New York. The partners expect...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Jan 6, 2017
Clinical News

Trabodenoson: Ph III MATrX-1 data

Top-line data from the double-blind, U.S. Phase III MATrX-1 trial in 303 patients with primary open-angle glaucoma or ocular hypertension showed that once-daily 3% and 6% and twice-daily 4.5% topical trabodenoson for 3 months all...
BC Extra | Jan 3, 2017
Clinical News

Inotek plummets on Phase III glaucoma miss

Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) sank $4.35 (71%) to $1.75 after it said trabodenoson ( INO-8875 ) monotherapy missed the primary endpoint of the Phase III MATrX-1 trial to treat primary open-angle glaucoma or ocular hypertension. Inotek said...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
Items per page:
1 - 10 of 86